Bosch Packaging Technology plans to introduce its latest R&D device for continuous production of oral solid dosage (OSD) at Achema 2018, a trade fair to be held next month in Frankfurt, Germany.
Known as Xelum R&D, the new platform is designed to reduce the time to market and ensure optimum dosing of active pharmaceutical ingredients (APIs).
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Unlike the common complex mass flow rate, the Xelum R&D allows excipients and active ingredients to be dosed as a discrete mass, offering the ability to dose even smallest amounts of APIs of less than 1%.
Bosch subsidiary Hüttlin product manager Fritz-Martin Scholz said: “The new laboratory device is based on our Xelum production platform that we presented last year.
“The separated process steps of batch production take place one after the other and without interruption. This leads to shorter cycle times, lower production costs and high flexibility.”
According to Bosch, the system doses, mixes and granulates individual packages, known as X-keys, which continuously run through the process chain and are removed successively from the machine as packages into bins.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataScholz added: “This way we reduce not only process complexity, but also the system’s failure susceptibility, while increasing both accuracy and quality of the end product. Moreover, the product is traceable at all times.”
The company noted that process parameters are identical and can be directly transferred 1:1 because the Xelum R&D and the Xelum production platform use the same components for dosing, mixing and granulating.
The Xelum system uses fluid bed processors that are based on a technology developed by Bosch subsidiary Hüttlin.
